news-med.jpg

Evotec AG announces first nine-month 2017 results and corporate update

Strong operational and financial performance Expansion of leading external innovation platform through acquisition of aptuit Important milestone achievements and new ways of accelerating innovation Hamburg, Germany, 08 November 2017: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: ...

Topics: Corporate, Drug Development, Drug Discovery Read More

Evotec joins forces with Academic Leaders to accelerate Drug Discovery in kidney diseases and build “Neplex”

Collaboration aimed at developing novel “Nephron-on-a Chip” device to test drug candidates in human kidney: NEPLEX (“Nephron-on-a-Chip with Cellular and Extracellular Matrix Complexity”) Major step forward to the next generation Kidney Platform Hamburg, Germany, 06 November 2017: Evotec AG ...

Topics: Corporate, Drug Development, Drug Discovery Read More

New Research by Cyprotex on Transporter DDI Published in Pharmacology Research & Perspectives

New research by Cyprotex in the field of metformin drug-drug interactions has been published in Pharmacology Research & Perspectives. The publication assists in further understanding the mechanism behind clinically observed DDIs with the common co-medication, metformin. Read our blog and download ...

Topics: Corporate, Drug Development, Drug Discovery Read More

Evotec and Tesaro Enter Strategic Partnership To Discover Novel Immuno-Oncology Agents

Discovery and development of inhibitors against Tesaro's Immuno-Oncology target utilising Evotec's comprehensive discovery and development platform Hamburg, Germany, 26 October 2017: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and TESARO, Inc. (“TESARO”) today announced a ...

Topics: Corporate, Drug Development, Drug Discovery Read More

Evotec Achieves First Milestone In Neurodegeneration Alliance With Celgene

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its strategic alliance with Celgene has reached a first milestone triggering revenues of $ 5.0 m to Evotec, which are recognised in the third quarter of 2017. The milestone is due to the successful completion ...

Topics: Corporate, Drug Development, Drug Discovery, Partner Research Organization Read More

Evotec and MaRS Innovation Establish Academic Bridge “LAB150” in Toronto

We are pleased to share the press release about the launch of “LAB150” announced by Evotec and MaRS Innovation.

Topics: Corporate, Drug Development, Drug Discovery, Partner Research Organization Read More

Evotec to Acquire Aptuit, Expanding Leadership in External Innovation

We are pleased to share the press release published today about the agreement between Evotec AG and Aptuit under which Evotec will acquire Aptuit.

Topics: Corporate, Acquisition, Drug Development, Drug Discovery, Contract Reseach Organization, Partner Research Organization, Integrated CMC, IND Enabling Read More

Read our article on Form Selection Problems in the Pharmaceutical Field

Our Material Sciences and API experts Matteo Daldosso, Zadeo Cimarosti and Brigida Allieri have recently published an article where they discuss about the "form selection problem in the pharmaceutical field" and the importance of X-Rays Powder Diffraction technique to respond to the implications ...

Topics: Drug Development, Active Pharmaceutical Ingredient, CMC, Partner Research Organization, Integrated CMC, Form selection, Material Sciences Read More

Aptuit Announces Strategic Provider Agreement with Regulus Therapeutics

Provides range of discovery, CMC and non-clinical services Greenwich, CT, June 8, 2017 - Dr. Jonathan Goldman, CEO, Aptuit LLC, announced a strategic provider relationship between Aptuit, a leading Partnership Research Organization, and Regulus Therapeutics Inc (Nasdaq:RGLS), an innovative ...

Topics: Drug design and discovery, Drug Development, Partner Research Organization, microRNA Read More